Loading page
Loading page
Loading substance route
Clinical anesthesia induction typically requires 3-6 mg/kg; coma induction 20 mg/kg. Doses reflect medical anesthetic use; recreational dosing data not available.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Classified as habit-forming with dependency risk, though recreational abuse is rare.
Carries a dependency risk as a barbiturate; recreational use is uncommon despite the potential for dependence.
Lethal blood levels may be as low as 1 mg/100 mL for short-acting barbiturates; lower concentrations may be lethal if other depressant drugs or alcohol are also present.
Rapid or repeated intravenous injection can cause severe hypotension progressing to shock; this risk is heightened in trauma patients or those with pre-existing cardiovascular compromise.
Respiratory depression including apnea, laryngospasm, and coughing may occur with excessive or overly rapid injection.
Vesicant properties can cause severe tissue necrosis and sloughing if extravasated during intravenous injection; proper intravenous technique is essential to avoid local damage.
Sodium thiopental was discovered in the early 1930s by Ernest H. Volwiler and Donalee L. Tabern while working for Abbott Laboratories. The compound was first administered to human beings on March 8, 1934, by Dr. Ralph M. Waters, who investigated its properties and found it produced short-term…
Previously FDA-approved as a prescription injectable anesthetic for intravenous administration. As a barbiturate, it is subject to controlled substance regulations. The injectable formulation was withdrawn from the US pharmaceutical market in January 2011.
11 sources cited